Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study

J. Tate Thigpen, John A. Blessing, Koen DeGeest, Katherine Y. Look, Howard D. Homesley

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Objectives. Carcinosarcomas of the ovary are rare; hence, although most patients recur after surgical resection or have metastatic disease at the time of diagnosis, only anecdotal information is available concerning the activity of cytotoxic drugs against these lesions. The Gynecologic Oncology Group (GOG) initiated a concerted effort to study cytotoxic therapy for these cancers in 1976. This report presents data on cisplatin, the first of the agents to be studied in this disease. Methods. One hundred thirty-six eligible patients with ovarian carcinosarcoma received cisplatin (50 mg/m2) every 3 weeks until disease progression or unacceptable toxicity. Results. Among 44 patients evaluable for response, one complete (2%) and eight partial (18%) responses resulted. An additional 10 (23%) patients exhibited stable disease, while 25 (57%) had increasing disease. Median progression-free survival in 130 patients evaluable for this endpoint was 5.2 months. Median survival in the same 130 patients was 11.7 months. Adverse effects ≥grade 2 among the 132 patients evaluable for toxicity included leukopenia (14%), neutropenia (17%), thrombocytopenia (2%), anemia (10%), nausea and vomiting (40%), azotemia (3%), neurotoxicity (4%), fever (2%), and tinnitus (1%). Conclusions. These data provide the first objective evidence that cisplatin is active as an initial therapy for patients who have carcinosarcoma of the ovary. The overall response rate (20%) is similar to that seen in carcinosarcomas of the uterus.

Original languageEnglish (US)
Pages (from-to)336-339
Number of pages4
JournalGynecologic oncology
Volume93
Issue number2
DOIs
StatePublished - May 1 2004

    Fingerprint

Keywords

  • Chemotherapy
  • Cisplatin
  • Ovarian carcinosarcomas

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this